Novo Nordisk Logo

Novo Nordisk

Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.

NOVO | CO

Overview

Corporate Details

ISIN(s):
DK0062498333 (+1 more)
LEI:
549300DAQ1CVT6CXN342
Country:
Denmark
Address:
Novo Alle 1, 2880 Bagsværd
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures innovative biological medicines and therapeutic devices. With a focus on driving change to defeat serious chronic diseases, the company's primary treatment areas include diabetes, obesity, and rare blood and endocrine disorders. Leveraging over 90 years of innovation, Novo Nordisk provides pharmaceutical products and services to patients worldwide, aiming to make its treatments accessible and improve health outcomes.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Novo Nordisk and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-10 07:00
Regulatory News Service
English 11.2 KB
2025-09-10 07:00
Earnings Release
English 151.5 KB
2025-08-19 13:37
Director's Dealing
English 17.4 KB
2025-08-19 13:37
Director's Dealing
English 144.5 KB
2025-08-12 14:25
Director's Dealing
English 144.4 KB
2025-08-12 14:25
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 17.4 KB
2025-08-08 15:15
Director's Dealing
English 144.5 KB
2025-08-07 17:30
Director's Dealing
English 159.1 KB
2025-08-07 17:30
Director's Dealing
English 30.5 KB
2025-08-06 07:30
Earnings Release
English 1.4 MB
2025-08-06 07:30
Earnings Release
English 11.9 KB
2025-07-29 13:35
Board/Management Information
English 12.0 KB
2025-07-29 13:35
Board/Management Information
English 176.8 KB
2025-07-29 13:01
Earnings Release
English 167.4 KB

Automate Your Workflow. Get a real-time feed of all Novo Nordisk filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Novo Nordisk via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Naturland Holding PLC Logo
A Hungarian company providing full-scale pharmaceutical manufacturing from R&D to sales.
United Kingdom NATUR
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
Novacyt Logo
Designs and supplies molecular diagnostic tests and PCR kits for human, veterinary, and food safety.
France ALNOV
Novartis AG Logo
Develops and markets innovative medicines globally using advanced science and technology.
Switzerland NOVN
NUFORMIX PLC Logo
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
United Kingdom NFX

Talk to a Data Expert

Have a question? We'll get back to you promptly.